GRPH News and Press, Graphite Bio Inc. From 05/17/22

The following slide deck was published by Graphite Bio, Inc. in conjunction with this event. For further details see: Graphite Bio Investor Presentation - Slideshow

The following slide deck was published by Graphite Bio, Inc. in conjunction with this event. For further details see: Graphite Bio (GRPH) Investor Presentation - Slideshow

Trial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be presented as an encore Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to...

Graphite Bio press release (NASDAQ:GRPH): Q1 GAAP EPS of -$0.48 misses by $0.09. As of March 31, 2022, cash, cash equivalents and investments in marketable securities totaled $352.1M. The company continues to expect this will fund its planned operations into the fourth quarter of 2024. For ...

GPH101 for sickle cell disease granted U.S. FDA Fast Track Designation; dosing of first patient in Phase 1/2 CEDAR clinical trial on track for second half of 2022, with initial proof-of-concept data anticipated in 2023 Oral presentation highlighting preclinical data for GPH102...

What to Know About Buying Penny Stocks on May 3rd, 2022 After an interesting start to May for penny stocks and blue chips, there is a lot for investors to know right now. While morning gainers like Forte Biosciences Inc. ( NASDAQ: FBRX ) and SoundHound AI Inc. ( NASDAQ: SOUN ) a...

GPH101 is an investigational next-generation gene-edited therapy designed to potentially provide a one-time cure for patients Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repa...

Accepted abstracts highlight next-generation gene editing programs GPH101 for sickle cell disease and GPH102 for beta-thalassemia Chief Scientific Officer Dr. Jane Grogan to participate in scientific symposium Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio, a...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, today announced the formation of its Scientific Advisory Board (SAB), which is initially co...